Stage III melanoma patients with lymph node metastases have high TRIM16 expression with a longer median survival (59 months) compared to patients with low TRIM16 expression (16 months)23, therefore we investigated the effect of WFA on melanoma cell migration. Here, TRIM16 is linked to metastatic malignant neoplasm in the lymph nodes.